Gene Therapy for Anti-Aging and Longevity: Current Insights, Comparative Strategies, and Future Directions

Aging- the Grand Therapeutic Challenge

Aging remains the primary risk factor for most chronic degenerative diseases, including cardiovascular disease, osteoporosis, sarcopenia, metabolic decline, and neurodegeneration. Over the decades, various therapeutic interventions, lifestyle modification, caloric restriction mimetics, small molecules, recombinant proteins, and monoclonal antibodies, have demonstrated moderate but tangible benefits in slowing age-related decline. However, these approaches typically target specific downstream symptoms or pathways, rather than the core, systemic mechanisms that drive aging as a whole.

Gene therapy has emerged as a transformative approach that can address aging at its root, enabling durable expression of protective factors within the body’s own cells. A prime example is the Klotho (KL) protein, a powerful endogenous regulator of metabolism, oxidative stress, inflammation, and mineral homeostasis. Notably, Roig-Soriano et al. (2025) demonstrated that systemic delivery of secreted Klotho (s-KL) via AAV9 vectors significantly extended lifespan and improved multi-organ function in wild-type aging mice, marking a new milestone for translational geroscience.

Comparative Overview of Anti-Aging Modalities

While gene therapy shows unique promise, other approaches, especially small molecules and antibody/protein therapies, continue to be highly relevant. The following table summarizes their core rationale, mechanisms, and representative examples (Table 1).

 

Table 1: Comparative Overview of Anti-Aging Modalities.

Therapeutic ModalityMechanism of ActionKey ExamplesMain Rationale/Outcome
Small MoleculesModulate intracellular pathways; regulate metabolism, senescence, autophagyRapamycin (mTOR inhibitor), Metformin (AMPK activator), Senolytics (Dasatinib + Quercetin), NAD⁺ boosters (NR, NMN)Delay age-associated diseases, clear senescent cells, enhance mitochondrial function
Antibody/Protein TherapyNeutralize pro-aging cytokines, supply exogenous protective proteinsAnti-IL-11 mAb, Anti-Myostatin, Recombinant Klotho proteinReduce inflammation/fibrosis, boost muscle regeneration, enhance resilience
Gene TherapyDeliver genetic material for sustained in vivo expression of anti-aging factorsAAV-sKL, TERT, Follistatin, Mitochondrial enzymes (TFAM)Long-term endogenous production of protective proteins, multi-tissue rejuvenation

 

Why Gene Therapy Represents a Paradigm Shift

Gene therapy fundamentally differs from other interventions by reprogramming cells to produce therapeutic proteins from within, achieving durable, regulated effects (Table 2).

In anti-aging, gene therapy typically involves viral vectors, most commonly adeno-associated viruses (AAVs), that deliver transgenes encoding proteins like s-Klotho, TERT (telomerase), or Follistatin. Once delivered, these vectors remain episomal or integrate minimally, allowing tissues to continuously produce the desired factor for months to years.

 

Table 2: Comparative Advantages and Limitations of Gene Therapy- and Protein/Antibody-Based Anti-Aging Therapies. 

DimensionGene TherapyProtein/Antibody Therapy
MechanismLong-term endogenous protein production via delivered gene cassetteDirect administration of recombinant proteins or monoclonal antibodies
Duration of EffectMonths to years after single administrationDays to weeks; repeated dosing needed
OnsetDelayed (weeks for expression ramp-up)Immediate (hours–days)
ReversibilityLimited; once transduced, difficult to fully reverseFully controllable; dosing can be adjusted or stopped
Safety RisksPotential insertional mutagenesis, immune responses to viral capsidsLower genomic risk; manageable immunogenicity
Cost StructureHigh upfront (vector production, administration), lower maintenanceHigh ongoing costs (repeat manufacturing, frequent infusions)
Tissue TargetingCustomizable vector tropism (e.g., AAV-PHP.B for CNS)Often limited by biodistribution (e.g., BBB crossing barriers)

Landmark Findings: The s-Klotho Gene Therapy Example

The landmark study by Roig-Soriano et al. (2025) offers compelling proof-of-concept evidence for gene therapy as a gerotherapeutic strategy. Using AAV9 vectors to deliver the secreted isoform of the Klotho gene in wild-type mice, the researchers achieved several significant outcomes. Notably, when treatment was initiated at mid-life (12 months in mice, roughly equivalent to 40 years in humans), median lifespan increased by 15–20%. In muscle tissue, the therapy reduced fibrosis, enhanced satellite cell proliferation, and improved regeneration in transplant models. Bone health also benefited, with increased trabecular volume and upregulation of osteogenic genes, effectively counteracting osteoporosis. In the central nervous system, the treatment elevated markers of hippocampal neurogenesis (e.g., DCX+), modulated glial activation, and shifted transcriptomic profiles toward anti-inflammatory and pro-phagocytic states. Importantly, the combined intravenous and intracerebroventricular delivery approach enabled robust gene expression in both peripheral tissues and the brain, overcoming the formidable challenge posed by the blood-brain barrier. This study builds on earlier findings showing that recombinant Klotho protein can transiently replicate these benefits, but only with frequent dosing due to its short half-life and limited CNS penetration.

Future Directions – Toward Next-Generation Gerotherapy

Building on the landmark findings of the Roig-Soriano study, the next generation of anti-aging gene therapies is poised to evolve through several critical innovations. One key area is the development of enhanced delivery platforms. Engineered adeno-associated viruses (AAVs), such as AAV-PHP.B, offer improved penetration across the blood-brain barrier, enabling less invasive targeting of central nervous system tissues. Additionally, the use of tissue-specific promoters can help minimize off-target effects, increasing both efficacy and safety.

Another promising direction is the adoption of combinatorial gene therapy approaches. By co-delivering multiple genes, such as secreted Klotho (sKL), telomerase reverse transcriptase (TERT), and sirtuin 6 (SIRT6), therapies could address several hallmarks of aging simultaneously, including genomic instability, mitochondrial dysfunction, and inflammation, yielding synergistic benefits. Closely linked to this is the need for regulated gene expression. The incorporation of inducible promoters or gene switches will allow clinicians to fine-tune transgene activity, offering an additional layer of control to reduce the risk of overexpression or adverse effects.

Translation to human applications will require rigorous validation in large-animal models and non-human primates. These studies are essential to assess the long-term durability of gene expression, evaluate immune responses to vectors, and confirm that observed benefits in mice can be replicated in species more physiologically similar to humans. Finally, as gene therapies for aging approach clinical viability, the establishment of robust ethical and regulatory frameworks will be indispensable. Guidelines must address the societal implications of extending human lifespan, such as equitable access, safety oversight, and potential impacts on healthcare systems. Together, these future directions represent the pathway from experimental success to a transformative new era in human gerotherapy.

Conclusion

The field of gerotherapy is moving rapidly from hypothesis to practice. While small molecules and antibody/protein interventions remain indispensable, gene therapy uniquely enables lifelong, systemic rejuvenation through the body’s own machinery. The pioneering work on s-Klotho gene therapy illustrates this potential, demonstrating multi-organ, multi-pathway rejuvenation with a single intervention.

As vector design, delivery precision, and regulatory frameworks mature, gene therapy may shift the paradigm from treating individual age-related diseases to extending healthspan and functional longevity for entire populations.

Reference

Roig-Soriano, Joan et al. (2025). Long-term effects of s-KL treatment in wild-type mice: Enhancing longevity, physical well-being, and neurological resilience. Molecular Therapy,  33:1449 – 1465. DOI: 10.1016/j.ymthe.2025.02.030 

 

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

 

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025. DOI: 10.1016/j.omtm.2025.101541

2. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1.

4.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)